CR20190350A - INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS - Google Patents

INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS

Info

Publication number
CR20190350A
CR20190350A CR20190350A CR20190350A CR20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A
Authority
CR
Costa Rica
Prior art keywords
tgfß1
isoform
inhibitors
permisives
same
Prior art date
Application number
CR20190350A
Other languages
English (en)
Inventor
Constance Martin
Thomas Schurpf
Ashish Kalra
Kimberly Long
Alan Buckler
Gregory J Carven
Abhishek Datta
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of CR20190350A publication Critical patent/CR20190350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

En el presente documento se describe el uso terapéutico de inhibidores de TGFß1 isoforma-específicos, contexto-permisivos, en el tratamiento de enfermedades que implican la desregulación de TGFß1.
CR20190350A 2017-01-06 2018-01-05 INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS CR20190350A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US201762588626P 2017-11-20 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
CR20190350A true CR20190350A (es) 2019-11-15

Family

ID=61198888

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190350A CR20190350A (es) 2017-01-06 2018-01-05 INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS

Country Status (17)

Country Link
US (3) US20180207267A1 (es)
EP (1) EP3551658A1 (es)
JP (3) JP7157744B2 (es)
KR (2) KR20190098255A (es)
CN (2) CN117398457A (es)
AU (2) AU2018205231A1 (es)
BR (1) BR112019013908A2 (es)
CA (1) CA3049005A1 (es)
CL (1) CL2019001874A1 (es)
CO (1) CO2019007298A2 (es)
CR (1) CR20190350A (es)
DO (1) DOP2019000180A (es)
IL (2) IL267790A (es)
MX (1) MX2019008197A (es)
PE (1) PE20191661A1 (es)
PH (1) PH12019501575A1 (es)
WO (1) WO2018129329A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
WO2018129329A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
US12358992B2 (en) * 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US12252531B2 (en) 2018-07-11 2025-03-18 Scholar Rock, Inc. Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
PH12021551860A1 (en) * 2019-01-30 2022-05-16 Scholar Rock Inc Ltbp complex-specific inhibitors of tgf㟠and uses thereof
TW202102207A (zh) 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 對於癌病具有治療意義的生物標記
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
KR20250093432A (ko) 2019-08-28 2025-06-24 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
CA3167427A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
MX2022011892A (es) 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
WO2021195485A1 (en) * 2020-03-27 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021222316A2 (en) 2020-04-27 2021-11-04 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7591066B2 (ja) 2020-06-03 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
WO2022116877A1 (en) * 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CA3227318A1 (en) * 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982B2 (en) 2021-12-22 2026-04-16 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN119255993A (zh) 2022-03-22 2025-01-03 奥托泰利克生物公司 噻唑衍生物化合物及其用途
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117721079B (zh) * 2024-01-26 2025-03-11 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026089992A1 (en) 2024-10-21 2026-04-30 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
SG196697A1 (en) * 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
KR20150080033A (ko) * 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
PH12013502489B1 (en) * 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
HK1205522A1 (en) * 2011-11-08 2015-12-18 辉瑞公司 Methods of treating inflammatory disorders using anti-m-csf antibodies
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
HUE052232T2 (hu) * 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA2973978A1 (en) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
WO2018129329A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Also Published As

Publication number Publication date
WO2018129329A1 (en) 2018-07-12
DOP2019000180A (es) 2019-09-15
AU2025203555A9 (en) 2026-03-12
US20180207267A1 (en) 2018-07-26
KR20190098255A (ko) 2019-08-21
CO2019007298A2 (es) 2019-07-31
AU2018205231A1 (en) 2019-07-18
IL304416A (en) 2023-09-01
AU2025203555A1 (en) 2025-06-05
BR112019013908A2 (pt) 2020-02-04
CN110382530A (zh) 2019-10-25
CA3049005A1 (en) 2018-07-12
JP2022188226A (ja) 2022-12-20
IL267790A (en) 2019-09-26
JP2020503362A (ja) 2020-01-30
PE20191661A1 (es) 2019-11-11
MX2019008197A (es) 2019-09-11
US20240016928A1 (en) 2024-01-18
US20190209682A1 (en) 2019-07-11
JP2025000891A (ja) 2025-01-07
JP7157744B2 (ja) 2022-10-20
PH12019501575A1 (en) 2019-11-04
KR20240137126A (ko) 2024-09-19
EP3551658A1 (en) 2019-10-16
CL2019001874A1 (es) 2019-12-06
CN117398457A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2019001669A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2018010993A (es) Derivados de icariina e icaritina.
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2019006950A (es) Metodos para tratar la sinaptopatia coclear.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.